Benutzer: Gast  Login
Titel:

Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial.

Dokumenttyp:
Journal Article
Autor(en):
Heilig, C E; Horak, P; Kreutzfeldt, S; Teleanu, V; Mock, A; Renner, M; Bhatti, I A; Hutter, B; Hüllein, J; Fröhlich, M; Uhrig, S; Süße, H; Heiligenthal, L; Ochsenreither, S; Illert, A L; Vogel, A; Desuki, A; Heinemann, V; Heidegger, S; Bitzer, M; Scheytt, M; Brors, B; Hübschmann, D; Baretton, G; Stenzinger, A; Steindorf, K; Benner, A; Jäger, D; Heining, C; Glimm, H; Fröhling, S; Schlenk, R F
Abstract:
BACKGROUND: Approvals of cancer therapeutics are primarily disease entity specific. Current molecular diagnostic approaches frequently identify actionable alterations in rare cancers or rare subtypes of common cancers for which the corresponding treatments are not approved and unavailable within clinical trials due to entity-related eligibility criteria. Access may be negotiated with health insurances. However, approval rates vary, and critical information required for a scientific evaluation of...     »
Zeitschriftentitel:
ESMO Open
Jahr:
2021
Band / Volume:
6
Heft / Issue:
6
Volltext / DOI:
doi:10.1016/j.esmoop.2021.100310
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/34808524
TUM Einrichtung:
608; III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX